Preferential inhibition of acetylcholinesterase molecular forms in rat brain
- PMID: 1528356
- DOI: 10.1007/BF00969897
Preferential inhibition of acetylcholinesterase molecular forms in rat brain
Abstract
The effect of eight different acetylcholinesterase inhibitors (AChEIs) on the activity of acetylcholinesterase (AChE) molecular forms was investigated. Aqueous-soluble and detergent-soluble AChE molecular forms were separated from rat brain homogenate by sucrose density sedimentation. The bulk of soluble AChE corresponds to globular tetrameric (G4), and monomeric (G1) forms. Heptylphysostigmine (HEP) and diisopropylfluorophosphate were more selective for the G1 than for the G4 form in aqueous-soluble extract. Neostigmine showed slightly more selectivity for the G1 form both in aqueous- and detergent-soluble extracts. Other drugs such as physostigmine, echothiophate, BW284C51, tetrahydroaminoacridine, and metrifonate inhibited both aqueous- and detergent-soluble AChE molecular forms with similar potency. Inhibition of aqueous-soluble AChE by HEP was highly competitive with Triton X-100 in a gradient, indicating that HEP may bind to a detergent-sensitive non-catalytic site of AChE. These results suggest a differential sensitivity among AChE molecular forms to inhibition by drugs through an allosteric mechanism. The application of these properties in developing AChEIs for treatment of Alzheimer disease is considered.
Similar articles
-
Are soluble and membrane-bound rat brain acetylcholinesterase different?Neurochem Res. 1990 Nov;15(11):1065-72. doi: 10.1007/BF01101705. Neurochem Res. 1990. PMID: 2089266
-
Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain.Brain Res. 1992 Sep 4;589(2):307-12. doi: 10.1016/0006-8993(92)91291-l. Brain Res. 1992. PMID: 1393597
-
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7. Acta Biol Hung. 2003. PMID: 14535624
-
RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?Alzheimer Dis Assoc Disord. 2000 Oct-Dec;14(4):216-27. doi: 10.1097/00002093-200010000-00006. Alzheimer Dis Assoc Disord. 2000. PMID: 11186600 Review.
-
Brain aryl acylamidase.Int J Biochem. 1982;14(12):1037-42. doi: 10.1016/0020-711x(82)90157-4. Int J Biochem. 1982. PMID: 6757008 Review.
Cited by
-
Differential inhibition of soluble and membrane-bound acetylcholinesterase forms from mouse brain by choline esters with an acyl moiety of an intermediate size.Neurochem Res. 1994 Jul;19(7):799-803. doi: 10.1007/BF00967447. Neurochem Res. 1994. PMID: 7969748
-
Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.Curr Top Med Chem. 2024;24(19):1699-1737. doi: 10.2174/0115680266299847240328045737. Curr Top Med Chem. 2024. PMID: 38566385 Review.
-
Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?Drugs Aging. 2001;18(12):891-8. doi: 10.2165/00002512-200118120-00001. Drugs Aging. 2001. PMID: 11888344 Review.
-
Effects per se of organic solvents in the cerebral acetylcholinesterase of rats.Neurochem Res. 2005 Mar;30(3):379-84. doi: 10.1007/s11064-005-2612-5. Neurochem Res. 2005. PMID: 16018582
-
Metrifonate.Drugs Aging. 1997 Dec;11(6):490-6. doi: 10.2165/00002512-199711060-00008. Drugs Aging. 1997. PMID: 9413706 Review. No abstract available.